Seroatlas · Human Serome Atlas

VSIR

V-type immunoglobulin domain-containing suppressor of T-cell activation

Also known as: B7-H5, B7H5, C10orf54, Dies1, GI24, PD-1H, SISP1, VISTA, VISTA_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H7M9
Gene: VSIR
Ensembl: ENSG00000107738
Chromosome: 10
Canonical length: 311 aa
Protein class: Predicted membrane proteins

OverviewNCBI Gene

Enables endopeptidase activator activity; enzyme binding activity; and identical protein binding activity. Involved in several processes, including negative regulation of cytokine production; positive regulation of metabolic process; and regulation of T cell activation. Located in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

311 residues, UniProt reviewed canonical sequence.

>Q9H7M9|VSIR
     1  MGVPTALEAG SWRWGSLLFA LFLAASLGPV AAFKVATPYS LYVCPEGQNV TLTCRLLGPV
    61  DKGHDVTFYK TWYRSSRGEV QTCSERRPIR NLTFQDLHLH HGGHQAANTS HDLAQRHGLE
   121  SASDHHGNFS ITMRNLTLLD SGLYCCLVVE IRHHHSEHRV HGAMELQVQT GKDAPSNCVV
   181  YPSSSQDSEN ITAAALATGA CIVGILCLPL ILLLVYKQRQ AASNRRAQEL VRMDSNIQGI
   241  ENPGFEASPP AQGIPEAKVR HPLSYVAQRQ PSESGRHLLS EPSTPLSPPG PGDVFFPSLD
   301  PVPDSPNFEV I

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VSIR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.46
Highest tissue expression: 88 nTPM

Expression across tissuesHPA

Tissue

spleen: 88 nTPM
bone marrow: 77 nTPM
adipose tissue: 39 nTPM
lung: 34 nTPM
appendix: 30 nTPM
breast: 28 nTPM

Single-cell type

neutrophils: 1,249 nCPM
syncytiotrophoblasts: 844 nCPM
extravillous trophoblasts: 424 nCPM
cytotrophoblasts: 409 nCPM
monocytes: 387 nCPM
esophageal apical cells: 350 nCPM

Immune cell

neutrophil: 1,008 nTPM
eosinophil: 769 nTPM
total PBMC: 471 nTPM
non-classical monocyte: 437 nTPM
classical monocyte: 401 nTPM
intermediate monocyte: 372 nTPM

Brain region

medulla oblongata: 43 nTPM
thalamus: 38 nTPM
midbrain: 33 nTPM
hypothalamus: 31 nTPM
basal ganglia: 30 nTPM
spinal cord: 30 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.47
gnomAD pLI: 0.76
DepMap mean gene effect: 0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

Immunoglobulin domain subtype
Immunoglobulin-like domain
Immunoglobulin V-set domain
Immunoglobulin-like fold
Immunoglobulin-like domain superfamily
Immunoglobulin V-set domain
V-type immunoglobulin domain-containing suppressor of T-cell activation

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VSIR as an antibody target. Whether an autoantibody or antibody against VSIR could matter depends on whether native VSIR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VSIR is annotated at the cell surface, where native VSIR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label VSIR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...